Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen

  • Authors:
    • Alessio Cortellini
    • Katia Cannita
    • Alessandro Parisi
    • Olga Venditti
    • Paola Lanfiuti Baldi
    • Berardo De Berardis
    • Roberto Vicentini
    • Vincenzo Vicentini
    • Lucilla Verna
    • Giampiero Porzio
    • Corrado Ficorella
  • View Affiliations

  • Published online on: June 6, 2018     https://doi.org/10.3892/or.2018.6475
  • Pages: 803-812
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To date, there is no consensus regarding first‑line chemotherapy for patients with HER2‑negative, locally advanced/metastatic gastric cancer (a/m GC). In the present study we reported a retrospective case‑series of patients treated with a weekly regimen containing timed‑flat infusion of 5‑fluorouracil (TFI/5‑FU), docetaxel and oxaliplatin. From June 2007 to July 2017, 32 consecutive a/m GC patients were treated with first‑line standard (st) or modulated (mod) ‘FD/FOx’ regimen: Weekly 12 h (from 10.00 p.m. to 10.00 a.m.) TFI/5‑FU for two consecutive nights at 900 mg/m2/day, associated to weekly alternating docetaxel, 50 mg/m2 and oxaliplatin, 80 mg/m2. The median age of the patients was 60 years and their Eastern Cooperative Oncology Group‑performance status (ECOG‑PS) was as follows: i) ECOG‑PS 0/1, (n=28, 87.5%); and ii) ECOG‑PS 2 (n=4, 12.5%). Patient activity, efficacy and safety data were collected and subgroup analyses were conducted among patients treated with st and mod FD/FOx. In the intention‑to‑treat (ITT) analysis, the objective response rate (ORR) was 75% (95% CI, 53‑90) and the disease control rate (DCR) was 87.5% (95% CI, 67.6‑97.3). After a median follow‑up of 16 months, median progression‑free survival (PFS) and median overall survival (OS) were 14.0 and 19.0 months, respectively. The received dose‑intensities were ~80% of the standard doses for each agent. The most relevant treatment‑related grade 3 adverse events were: Neutropenia (40.6%), asthenia (18.7%) and diarrhea (18.7%). The only treatment‑related grade 4 adverse event was neutropenia (9.3%). No febrile neutropenia was observed and none of the patients died as a result of adverse events. FD/FOx regimen appeared to be a feasible option as a first‑line treatment of a/m GC patients, especially in case of high‑tumor burden, with the need of rapid tumor shrinkage and disease‑related symptoms palliation.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 40 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cortellini A, Cannita K, Parisi A, Venditti O, Lanfiuti Baldi P, De Berardis B, Vicentini R, Vicentini V, Verna L, Porzio G, Porzio G, et al: Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. Oncol Rep 40: 803-812, 2018
APA
Cortellini, A., Cannita, K., Parisi, A., Venditti, O., Lanfiuti Baldi, P., De Berardis, B. ... Ficorella, C. (2018). Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. Oncology Reports, 40, 803-812. https://doi.org/10.3892/or.2018.6475
MLA
Cortellini, A., Cannita, K., Parisi, A., Venditti, O., Lanfiuti Baldi, P., De Berardis, B., Vicentini, R., Vicentini, V., Verna, L., Porzio, G., Ficorella, C."Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen". Oncology Reports 40.2 (2018): 803-812.
Chicago
Cortellini, A., Cannita, K., Parisi, A., Venditti, O., Lanfiuti Baldi, P., De Berardis, B., Vicentini, R., Vicentini, V., Verna, L., Porzio, G., Ficorella, C."Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen". Oncology Reports 40, no. 2 (2018): 803-812. https://doi.org/10.3892/or.2018.6475